SCHEMBL17316631

SCHEMBL17316631

O=C(O)Cc1ccc(N2CC[C@H](F)C2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 3/20 0.51
ITGA2B P08514 3/20 0.51
CASR P41180 2/20 0.48
NOTUM Q6P988 4/20 0.48
POLB P06746 2/20 0.46
NSD2 O96028 1/20 0.46
GRK2 P25098 1/20 0.46
CASP6 P55212 1/20 0.46
CTDSP1 Q9GZU7 1/20 0.46
KLKB1 P03952 1/20 0.45
CTSB P07858 1/20 0.45
QPCT Q16769 1/20 0.45
ME3 Q16798 1/20 0.44
FFAR4 Q5NUL3 3/20 0.43
HRH1 P35367 1/20 0.43
CCR3 P51677 1/20 0.43
KCNH2 Q12809 1/20 0.43
MCHR1 Q99705 1/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17316620 1.00 ITGB3 (0.51) ITGB3ITGA2BCASRNOTUMPOLB
SCHEMBL17316810 1.00 ITGB3 (0.51) ITGB3ITGA2BCASRNOTUMPOLB
SCHEMBL17316711 0.89 ITGB3 (0.51) ITGB3ITGA2BCASRPOLBNSD2
SCHEMBL11853729 0.81 ITGB3 (0.57) ITGB3ITGA2BCASRPOLBNSD2
SCHEMBL28881408 0.80 LIPE (0.46) POLB
SCHEMBL28341778 0.80 LIPE (0.46) POLB
SCHEMBL28341780 0.80 LIPE (0.46) POLB
SCHEMBL21624841 0.79 USP2 (0.64) ITGB3ITGA2BCASRPOLBNSD2
SCHEMBL11856653 0.79 RORC (0.49) ITGB3ITGA2BCASRPOLBNSD2
SCHEMBL17316378 0.79 CACNA1G (0.53) KLKB1ME3RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106414429-B Pyrazole compounds and their use as T-type calcium channel blockers 爱杜西亚药品有限公司 2020-01-03 CN disclosed
US-10065929-B2 Pyrazole compounds and their use as T-type calcium channel blockers IDORSIA PHARMACEUTICALS LTD (CH) 2018-09-04 US disclosed
US-9932314-B2 Pyrazole compounds and their use as T-type calcium channel blockers IDORSIA PHARMACEUTICALS LTD (CH) 2018-04-03 US disclosed
EP-3152199-A1 PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS Actelion Pharmaceuticals Ltd. (CH) 2017-04-12 EP disclosed
US-20170096399-A1 PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS IDORSIA PHARMACEUTICALS LTD (CH) 2017-04-06 US disclosed
WO-2015186056-A1 PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS ACTELION PHARMACEUTICALS LTD (CH) 2015-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10065929-B2 Pyrazole compounds and their use as T-type calcium channel blockers CACNA1E, CACNA1I, CACNA1G ITGB3 2120/4885ITGA2B 2736/4885CASR 113/4885
US-20170096399-A1 PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS CACNA1E, CACNA1I, CACNA1G ITGB3 2120/4885ITGA2B 2736/4885CASR 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.